Entasis Therapeutics Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Entasis Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014156
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Entasis Therapeutics Inc (Entasis) discovers and develops anti-infective products for drug-resistant bacterial infections. The company’s pipeline products include ETX2514, a potent inhibitor of class A, C, and D beta-lactamases intended to treat serious gram-negative infections, such as Acinetobacter baumannii; and ETX0914, a oral antibiotic for the treatment of uncomplicated gonorrhea. It provides drug discovery platform that concentrates on the development of antibacterials targeting serious gram-negative infections including pneumonia, infections of the blood, urinary tract infections, and infections following surgery. Entasis has developed robust clinical and pre-clinical pipeline of medicines. The company offers small-molecule programs to treat multidrug-resistant gram-negative infections. Entasis is headquartered in Waltham, Massachusetts, the US.

Entasis Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Entasis Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Entasis Therapeutics Raises Additional USD32 Million in Series B-1 Financing 11
Entasis Therapeutics Raises USD50 Million in Series B Financing 12
Entasis Therapeutics Raises USD40 Million in Series A Venture Financing 13
Partnerships 14
Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 14
Entasis Therapeutics Inc – Key Competitors 15
Entasis Therapeutics Inc – Key Employees 16
Entasis Therapeutics Inc – Locations And Subsidiaries 17
Head Office 17
Recent Developments 18
Corporate Communications 18
Apr 10, 2017: Entasis Appoints Mike Gutch as Chief Financial Officer and Chief Business Officer 18
Nov 29, 2016: Entasis Therapeutics appoints new board member 19
Nov 29, 2016: Entasis Therapeutics Names Greg Norden, Former Senior Vice President and Chief Financial Officer of Wyeth, to its Board of Directors 20
Product News 21
10/28/2016: Entasis Therapeutics to Present Data at IDWeek on ETX2514SUL, a Novel Drug Targeting Multidrug-Resistant Acinetobacter baumannii Infections 21
06/30/2017: Entasis Publishes Data Highlighting the Potent and Differentiated Activity of ETX2514 Combinations against Drug Resistant Gram-negative Bacteria Including Acinetobacter and Pseudomonas 22
06/07/2017: Entasis Therapeutics Presents Data on ETX2514 at ASM Microbe 2017 23
05/22/2017: Entasis Therapeutics to Present Data on ETX0282 at ASM Microbe 2017 24
05/22/2017: Entasis Therapeutics to Present Data on ETX1317 at ASM Microbe 2017 25
05/22/2017: Entasis Therapeutics to Present Data on ETX2514 at ASM Microbe 2017 26
Clinical Trials 27
Oct 26, 2016: Entasis Announces Initiation of Phase I Clinical Trial of ETX2514 27
Jun 28, 2016: Entasis Presents Data Supporting the Potential Clinical Utility of ETX2514, a Next-generation Beta-lactamase Inhibitor, at ASM Microbe 2016 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29

List of Tables
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Entasis Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Entasis Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Entasis Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Entasis Therapeutics Raises Additional USD32 Million in Series B-1 Financing 11
Entasis Therapeutics Raises USD50 Million in Series B Financing 12
Entasis Therapeutics Raises USD40 Million in Series A Venture Financing 13
Entasis Therapeutics and Global Antibiotic Research & Development Enter into Partnership 14
Entasis Therapeutics Inc, Key Competitors 15
Entasis Therapeutics Inc, Key Employees 16

★海外企業調査レポート[Entasis Therapeutics Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Securitas AB:戦略・SWOT・企業財務分析
    Securitas AB - Strategy, SWOT and Corporate Finance Report Summary Securitas AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Dassault Aviation SA (AM):企業の財務・戦略的SWOT分析
    Dassault Aviation SA (AM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Tyco International plc:企業のM&A・事業提携・投資動向
    Tyco International plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Tyco International plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Tradewinds Corporation Berhad:戦略・SWOT・企業財務分析
    Tradewinds Corporation Berhad - Strategy, SWOT and Corporate Finance Report Summary Tradewinds Corporation Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Bunzl plc (BNZL):企業の財務・戦略的SWOT分析
    Bunzl plc (BNZL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • ABPA Holdings Ltd:企業の戦略的SWOT分析
    ABPA Holdings Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • MedImmune LLC-製薬・医療分野:企業M&A・提携分析
    Summary MedImmune LLC (MedImmune), a subsidiary of AstraZeneca Plc, is a biotechnology company. It focuses on the research, development, manufacture and marketing of small molecules and biologics to address some of the major medical needs. The company develops therapeutic proteins, monoclonal antibo …
  • Itochu Chemical Frontier Corp-製薬・医療分野:企業M&A・提携分析
    Summary Itochu Chemical Frontier Corp (ICF), formerly Ando Kaseihin KK, a subsidiary of Itochu Corporation, is a chemical company that manufactures and markets chemical products. The company operates in intermediate chemical division, silicone and adhesive division, osaka and nagoya division, perfor …
  • Interfor Corp:企業の戦略・SWOT・財務情報
    Interfor Corp - Strategy, SWOT and Corporate Finance Report Summary Interfor Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • South32 Ltd:企業の戦略・SWOT・財務情報
    South32 Ltd - Strategy, SWOT and Corporate Finance Report Summary South32 Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • AmerisourceBergen Corp (ABC):製薬・医療:M&Aディール及び事業提携情報
    Summary AmerisourceBergen Corp (AmerisourceBergen) is a pharmaceutical sourcing and distribution services company that provides pharmaceutical products, business solutions and value-driving services that improve access to care. The company distributes a broad offering of brand-name, specialty brand- …
  • IndiPharm Inc-製薬・医療分野:企業M&A・提携分析
    Summary IndiPharm Inc (IndiPharm) is a clinical research organization that provides drug safety services to support clinical research and marketed products. The organization offers CRO services such as preparing and filing regulatory submissions, obtaining required import and export licenses, protoc …
  • Iamgold Corporation:企業のM&A・事業提携・投資動向
    Iamgold Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Iamgold Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • The Pack Corporation:企業の戦略・SWOT・財務分析
    The Pack Corporation - Strategy, SWOT and Corporate Finance Report Summary The Pack Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • DBV Technologies SA (DBV):企業の財務・戦略的SWOT分析
    Summary DBV Technologies SA (DBV Technologies) is a biopharmaceutical company which develops self-administered and non-invasive therapies to treat food allergies and other immunological diseases. Its product pipeline includes Viaskin peanut, Viaskin milk and Viaskin egg indicated for the treatment o …
  • Thames Water Utilities Ltd:企業の戦略・SWOT・財務情報
    Thames Water Utilities Ltd - Strategy, SWOT and Corporate Finance Report Summary Thames Water Utilities Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Bureau Veritas SA (BVI):電力:M&Aディール及び事業提携情報
    Summary Bureau Veritas SA (Bureau Veritas) is a provider of testing, inspection and certification services. The company offers asset management, certification, consulting, inspection and audits, testing and analysis, and training. It serves aeronautics, agriculture, automotive, construction and real …
  • Penumbra Inc (PEN):企業の財務・戦略的SWOT分析
    Penumbra Inc (PEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Bayer AG (BAYN):医療機器:M&Aディール及び事業提携情報
    Summary Bayer AG (Bayer) carries out the research, development, production and commercialization of products for human and animal health care, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology and other indications. The company's pr …
  • LMI Aerospace, Inc.:企業の戦略的SWOT分析
    LMI Aerospace, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆